Cipla is bracing for significant revenue and margin headwinds after the anticipated expiry of its Revlimid (lenalidomide) patent next year—set to shave off around 140–240 bps from FY26 margins, with Elara Capital forecasting a further 300 bps contraction in FY27 . This

Continue ReadingCipla patent expiry.